Peregrine Capital Management’s West Pharmaceutical WST Stock Holding History

Peregrine Capital Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,759	Closed	-$724K	–	352
2025 Q3	$724K	Hold	2,759	–	–	0.02%	267
2025 Q2	$604K	Sell	2,759 -1,211	-31%	-$259K	0.02%	269
2025 Q1	$889K	Hold	3,970	–	–	0.03%	267
2024 Q4	$1.3M	Hold	3,970	–	–	0.04%	258
2024 Q3	$1.19M	Buy	3,970 +1,050	+36%	+$322K	0.04%	263
2024 Q2	$962K	Hold	2,920	–	–	0.03%	273
2024 Q1	$1.16M	Hold	2,920	–	–	0.03%	265
2023 Q4	$1.03M	Sell	2,920 -459	-14%	-$162K	0.03%	261
2023 Q3	$1.27M	Sell	3,379 -859	-20%	-$332K	0.04%	253
2023 Q2	$1.62M	Buy	4,238 +699	+20%	+$250K	0.04%	252
2023 Q1	$1.23M	Sell	3,539 -1,150	-25%	-$336K	0.04%	249
2022 Q4	$1.1M	Hold	4,689	–	–	0.03%	260
2022 Q3	$1.15M	Hold	4,689	–	–	0.04%	261
2022 Q2	$1.42M	Hold	4,689	–	–	0.04%	258
2022 Q1	$1.93M	Hold	4,689	–	–	0.05%	256
2021 Q4	$2.2M	Hold	4,689	–	–	0.04%	255
2021 Q3	$1.99M	Hold	4,689	–	–	0.04%	256
2021 Q2	$1.68M	Hold	4,689	–	–	0.03%	264
2021 Q1	$1.32M	Hold	4,689	–	–	0.02%	276
2020 Q4	$1.33M	Buy	+4,689	New	+$1.32M	0.03%	267

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Peregrine Capital Management's WST Position: Q4 2025 in Review

Peregrine Capital Management sold out of West Pharmaceutical (WST) in Q4 2025, closing a stake of 2,759 shares — an estimated $724K sold.

Peregrine Capital Management first reported a position in WST in Q4 2020 and held it in 20 quarters. The position peaked at $2.2M in Q4 2021. 803 funds tracked by Wall St. Rank hold WST as of Q4 2025.

Peregrine Capital Management reported no remaining West Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Peregrine Capital Management sold 2,759 West Pharmaceutical shares in Q4 2025, an estimated $724K.
Peregrine Capital Management first reported a position in West Pharmaceutical in Q4 2020 and held it in 20 quarters.
Peregrine Capital Management's West Pharmaceutical position peaked at $2.2M in Q4 2021.
803 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2025.

Based on Peregrine Capital Management's 13F filing for Q4 2025, filed 28 Jan 2026.